Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

From bladder to upper urinary tract: Unveiling the epidemiological dynamics of urothelial carcinoma. Clinical burden of recurrence among older adults with muscle invasive bladder cancer undergoing tri ...

Disparities in Endometrial Cancer Mortality: Will Increasing Use of Targeted Therapies Widen the Gap? Urothelial carcinoma (UC) is the most common malignancy of the urinary tract, with urothelial ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

Pre-specified thresholds for statistical significance were not met. Nivolumab plus ipilimumab did not improve overall survival (OS) when compared to chemotherapy in a phase 3 trial of patients with ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...